51
|
Napoli C, Zullo A, Picascia A, Infante T, Mancini FP. Recent advances in proteomic technologies applied to cardiovascular disease. J Cell Biochem 2013; 114:7-20. [PMID: 22886784 DOI: 10.1002/jcb.24307] [Citation(s) in RCA: 17] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/30/2012] [Accepted: 07/26/2012] [Indexed: 12/12/2022]
Abstract
In recent years, the diagnosis of cardiovascular disease (CVD) has increased its potential, also thanks to mass spectrometry (MS) proteomics. Modern MS proteomics tools permit analyzing a variety of biological samples, ranging from single cells to tissues and body fluids, like plasma and urine. This approach enhances the search for informative biomarkers in biological samples from apparently healthy individuals or patients, thus allowing an earlier and more precise diagnosis and a deeper comprehension of pathogenesis, development and outcome of CVD to further reduce the enormous burden of this disease on public health. In fact, many differences in protein expression between CVD-affected and healthy subjects have been detected, but only a few of them have been useful to establish clinical biomarkers because they did not pass the verification and validation tests. For a concrete clinical support of MS proteomics to CVD, it is, therefore, necessary to: ameliorate the resolution, sensitivity, specificity, throughput, precision, and accuracy of MS platform components; standardize procedures for sample collection, preparation, and analysis; lower the costs of the analyses; reduce the time of biomarker verification and validation. At the same time, it will be fundamental, for the future perspectives of proteomics in clinical trials, to define the normal protein maps and the global patterns of normal protein levels, as well as those specific for the different expressions of CVD.
Collapse
Affiliation(s)
- Claudio Napoli
- Department of General Pathology, Excellence Research Centre on Cardiovascular Disease, U.O.C. Immunohematology, Transfusion Medicine and Transplant Immunology [SIMT], Regional Reference Laboratory of Transplant Immunology [LIT], Azienda Ospedaliera Universitaria (AOU), 1st School of Medicine, Second University of Naples, 80138 Naples, Italy.
| | | | | | | | | |
Collapse
|
52
|
Molacek J, Mares J, Treska V, Houdek K, Baxa J. Proteomic analysis of the abdominal aortic aneurysm wall. Surg Today 2013; 44:142-51. [PMID: 23519648 PMCID: PMC3898145 DOI: 10.1007/s00595-012-0480-6] [Citation(s) in RCA: 6] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/21/2012] [Accepted: 10/26/2012] [Indexed: 11/28/2022]
Abstract
PURPOSES A ruptured AAA (rAAA) is a common cause of death in males over 60 years of age, and the global mortality from rAAA exceeds 80 %. The pathological processes occurring in the wall of the developing AAA are still unclear. The potential pathophysiological mechanisms underlying aortic aneurysms have been examined by many studies using immunohistochemistry and were, therefore, targeted at specific, preselected protein antigens. METHODS We collected samples of tissue from anterior wall of an aneurysm sac from 15 patients indicated for AAA resection (group A) during the period from 2010 to 2011. These samples were subjected to a proteomic analysis. In addition, we collected control samples of identical aortic tissue from 10 heart-beating deceased organ donors (group B). RESULTS A total of 417 differentially expressed protein fractions were identified, 18 of which were only detected in the healthy controls, while 85 were specific for aneurysm tissue and 314 were detectable in both groups. In 175 protein fractions, the gel-derived spot volumes differed significantly between aneurismal and healthy aortic tissue. CONCLUSIONS We found a significant difference in the proteome of the AAA tissue and non-dilated aortic tissue. We demonstrated that the AAA proteome is considerably richer and more varied than the healthy and atherosclerotic aorta. We believe that our results clearly demonstrate a completely different etiopathogenesis of atherosclerosis and aneurismal disease.
Collapse
Affiliation(s)
- Jiri Molacek
- School of Medicine in Pilsen, Charles University in Prague, Husova 3, 306 05, Pilsen, Czech Republic,
| | | | | | | | | |
Collapse
|
53
|
Boytard L, Spear R, Chinetti-Gbaguidi G, Acosta-Martin AE, Vanhoutte J, Lamblin N, Staels B, Amouyel P, Haulon S, Pinet F. Role of Proinflammatory CD68
+
Mannose Receptor
−
Macrophages in Peroxiredoxin-1 Expression and in Abdominal Aortic Aneurysms in Humans. Arterioscler Thromb Vasc Biol 2013; 33:431-8. [DOI: 10.1161/atvbaha.112.300663] [Citation(s) in RCA: 59] [Impact Index Per Article: 5.4] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/21/2022]
Affiliation(s)
- Ludovic Boytard
- From the INSERM, U744 (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.), INSERM, U1011 (G.C.-G., J.V, B.S.), and INSERM, U1008 (S.H.), Lille, France; Institut Pasteur de Lille, Lille, France (L.B., R.S., G.C.-G., A.E.A.-M., J.V., N.L., B.S., P.A., F.P.); Univ Lille Nord de France, IFR142, Lille, France (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.); Centre Hospitalier Régional et Universitaire de Lille, Lille, France (R.S., N.L., P.A., S.H., F.P.); and Univ Lille Nord de France, IFR114, Lille, France (G.C.-G., J
| | - Rafaelle Spear
- From the INSERM, U744 (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.), INSERM, U1011 (G.C.-G., J.V, B.S.), and INSERM, U1008 (S.H.), Lille, France; Institut Pasteur de Lille, Lille, France (L.B., R.S., G.C.-G., A.E.A.-M., J.V., N.L., B.S., P.A., F.P.); Univ Lille Nord de France, IFR142, Lille, France (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.); Centre Hospitalier Régional et Universitaire de Lille, Lille, France (R.S., N.L., P.A., S.H., F.P.); and Univ Lille Nord de France, IFR114, Lille, France (G.C.-G., J
| | - Giulia Chinetti-Gbaguidi
- From the INSERM, U744 (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.), INSERM, U1011 (G.C.-G., J.V, B.S.), and INSERM, U1008 (S.H.), Lille, France; Institut Pasteur de Lille, Lille, France (L.B., R.S., G.C.-G., A.E.A.-M., J.V., N.L., B.S., P.A., F.P.); Univ Lille Nord de France, IFR142, Lille, France (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.); Centre Hospitalier Régional et Universitaire de Lille, Lille, France (R.S., N.L., P.A., S.H., F.P.); and Univ Lille Nord de France, IFR114, Lille, France (G.C.-G., J
| | - Adelina E. Acosta-Martin
- From the INSERM, U744 (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.), INSERM, U1011 (G.C.-G., J.V, B.S.), and INSERM, U1008 (S.H.), Lille, France; Institut Pasteur de Lille, Lille, France (L.B., R.S., G.C.-G., A.E.A.-M., J.V., N.L., B.S., P.A., F.P.); Univ Lille Nord de France, IFR142, Lille, France (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.); Centre Hospitalier Régional et Universitaire de Lille, Lille, France (R.S., N.L., P.A., S.H., F.P.); and Univ Lille Nord de France, IFR114, Lille, France (G.C.-G., J
| | - Jonathan Vanhoutte
- From the INSERM, U744 (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.), INSERM, U1011 (G.C.-G., J.V, B.S.), and INSERM, U1008 (S.H.), Lille, France; Institut Pasteur de Lille, Lille, France (L.B., R.S., G.C.-G., A.E.A.-M., J.V., N.L., B.S., P.A., F.P.); Univ Lille Nord de France, IFR142, Lille, France (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.); Centre Hospitalier Régional et Universitaire de Lille, Lille, France (R.S., N.L., P.A., S.H., F.P.); and Univ Lille Nord de France, IFR114, Lille, France (G.C.-G., J
| | - Nicolas Lamblin
- From the INSERM, U744 (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.), INSERM, U1011 (G.C.-G., J.V, B.S.), and INSERM, U1008 (S.H.), Lille, France; Institut Pasteur de Lille, Lille, France (L.B., R.S., G.C.-G., A.E.A.-M., J.V., N.L., B.S., P.A., F.P.); Univ Lille Nord de France, IFR142, Lille, France (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.); Centre Hospitalier Régional et Universitaire de Lille, Lille, France (R.S., N.L., P.A., S.H., F.P.); and Univ Lille Nord de France, IFR114, Lille, France (G.C.-G., J
| | - Bart Staels
- From the INSERM, U744 (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.), INSERM, U1011 (G.C.-G., J.V, B.S.), and INSERM, U1008 (S.H.), Lille, France; Institut Pasteur de Lille, Lille, France (L.B., R.S., G.C.-G., A.E.A.-M., J.V., N.L., B.S., P.A., F.P.); Univ Lille Nord de France, IFR142, Lille, France (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.); Centre Hospitalier Régional et Universitaire de Lille, Lille, France (R.S., N.L., P.A., S.H., F.P.); and Univ Lille Nord de France, IFR114, Lille, France (G.C.-G., J
| | - Philippe Amouyel
- From the INSERM, U744 (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.), INSERM, U1011 (G.C.-G., J.V, B.S.), and INSERM, U1008 (S.H.), Lille, France; Institut Pasteur de Lille, Lille, France (L.B., R.S., G.C.-G., A.E.A.-M., J.V., N.L., B.S., P.A., F.P.); Univ Lille Nord de France, IFR142, Lille, France (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.); Centre Hospitalier Régional et Universitaire de Lille, Lille, France (R.S., N.L., P.A., S.H., F.P.); and Univ Lille Nord de France, IFR114, Lille, France (G.C.-G., J
| | - Stephan Haulon
- From the INSERM, U744 (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.), INSERM, U1011 (G.C.-G., J.V, B.S.), and INSERM, U1008 (S.H.), Lille, France; Institut Pasteur de Lille, Lille, France (L.B., R.S., G.C.-G., A.E.A.-M., J.V., N.L., B.S., P.A., F.P.); Univ Lille Nord de France, IFR142, Lille, France (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.); Centre Hospitalier Régional et Universitaire de Lille, Lille, France (R.S., N.L., P.A., S.H., F.P.); and Univ Lille Nord de France, IFR114, Lille, France (G.C.-G., J
| | - Florence Pinet
- From the INSERM, U744 (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.), INSERM, U1011 (G.C.-G., J.V, B.S.), and INSERM, U1008 (S.H.), Lille, France; Institut Pasteur de Lille, Lille, France (L.B., R.S., G.C.-G., A.E.A.-M., J.V., N.L., B.S., P.A., F.P.); Univ Lille Nord de France, IFR142, Lille, France (L.B., R.S., A.E.A.-M., N.L., P.A., F.P.); Centre Hospitalier Régional et Universitaire de Lille, Lille, France (R.S., N.L., P.A., S.H., F.P.); and Univ Lille Nord de France, IFR114, Lille, France (G.C.-G., J
| |
Collapse
|
54
|
Abbasi A, Corpeleijn E, Postmus D, Gansevoort RT, de Jong PE, Gans ROB, Struck J, Schulte J, Hillege HL, van der Harst P, Peelen LM, Beulens JWJ, Stolk RP, Navis G, Bakker SJL. Peroxiredoxin 4, a novel circulating biomarker for oxidative stress and the risk of incident cardiovascular disease and all-cause mortality. J Am Heart Assoc 2012; 1:e002956. [PMID: 23316297 PMCID: PMC3541606 DOI: 10.1161/jaha.112.002956] [Citation(s) in RCA: 39] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 06/20/2012] [Accepted: 09/04/2012] [Indexed: 01/05/2023]
Abstract
BACKGROUND Oxidative stress has been suggested to play a key role in the development of cardiovascular disease (CVD). The aim of our study was to investigate the associations of serum peroxiredoxin 4 (Prx4), a hydrogen peroxide-degrading peroxidase, with incident CVD and all-cause mortality. We subsequently examined the incremental value of Prx4 for the risk prediction of CVD compared with the Framingham risk score (FRS). METHODS AND RESULTS We performed Cox regression analyses in 8141 participants without history of CVD (aged 28 to 75 years; women 52.6%) from the Prevention of Renal and Vascular End-stage Disease (PREVEND) study in Groningen, The Netherlands. Serum Prx4 was measured by an immunoluminometric assay in baseline samples. Main outcomes were: (1) incident CVD events or CVD mortality and (2) all-cause mortality during a median follow-up of 10.5 years. In total, 708 participants (7.8%) developed CVD events or CVD mortality, and 517 participants (6.3%) died. Baseline serum Prx4 levels were significantly higher in participants with incident CVD events or CVD mortality and in those who died than in participants who remained free of outcomes (both P<0.001). In multivariable models with adjustment for Framingham risk factors, hazard ratios were 1.16 (95% CI 1.06 to 1.27, P<0.001) for incident CVD events or CVD mortality and 1.17 (95% CI 1.06 to 1.29, P=0.003) for all-cause mortality per doubling of Prx4 levels. After the addition of Prx4 to the FRS, the net reclassification improvement was 2.7% (P=0.01) using 10-year risk categories of CVD. CONCLUSIONS Elevated serum Prx4 levels are associated with a significantly higher risk of incident CVD events or CVD mortality and all-cause mortality after adjustment for clinical risk factors. The addition of Prx4 to the FRS marginally improved risk prediction of future CVD.
Collapse
Affiliation(s)
- Ali Abbasi
- Department of Epidemiology, University of Groningen, University Medical Center Groningen, Groningen, the Netherlands.
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
55
|
Antibody phage display assisted identification of junction plakoglobin as a potential biomarker for atherosclerosis. PLoS One 2012; 7:e47985. [PMID: 23110151 PMCID: PMC3480477 DOI: 10.1371/journal.pone.0047985] [Citation(s) in RCA: 13] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/24/2012] [Accepted: 09/19/2012] [Indexed: 11/19/2022] Open
Abstract
To date, no plaque-derived blood biomarker is available to allow diagnosis, prognosis or monitoring of atherosclerotic vascular diseases. In this study, specimens of thrombendarterectomy material from carotid and iliac arteries were incubated in protein-free medium to obtain plaque and control secretomes for subsequent subtractive phage display. The selection of nine plaque secretome-specific antibodies and the analysis of their immunopurified antigens by mass spectrometry led to the identification of 22 proteins. One of them, junction plakoglobin (JUP-81) and its smaller isoforms (referred to as JUP-63, JUP-55 and JUP-30 by molecular weight) were confirmed by immunohistochemistry and immunoblotting with independent antibodies to be present in atherosclerotic plaques and their secretomes, coronary thrombi of patients with acute coronary syndrome (ACS) and macrophages differentiated from peripheral blood monocytes as well as macrophage-like cells differentiated from THP1 cells. Plasma of patients with stable coronary artery disease (CAD) (n = 15) and ACS (n = 11) contained JUP-81 at more than 2- and 14-fold higher median concentrations, respectively, than plasma of CAD-free individuals (n = 13). In conclusion, this proof of principle study identified and verified JUP isoforms as potential plasma biomarkers for atherosclerosis. Clinical validation studies are needed to determine its diagnostic efficacy and clinical utility as a biomarker for diagnosis, prognosis or monitoring of atherosclerotic vascular diseases.
Collapse
|
56
|
Laaksamo E, Tulamo R, Liiman A, Baumann M, Friedlander RM, Hernesniemi J, Kangasniemi M, Niemelä M, Laakso A, Frösen J. Oxidative Stress Is Associated With Cell Death, Wall Degradation, and Increased Risk of Rupture of the Intracranial Aneurysm Wall. Neurosurgery 2012; 72:109-17. [DOI: 10.1227/neu.0b013e3182770e8c] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022] Open
Abstract
Abstract
BACKGROUND:
The cause of rupture of intracranial aneurysms (IA) is not well understood. We previously demonstrated that loss of cells from the IA wall is associated with wall degeneration and rupture.
OBJECTIVE:
To investigate the mechanisms mediating cell death in the IA wall.
METHODS:
Snap-frozen tissue samples from aneurysm fundi were studied with terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL) staining and immunostaining (14 unruptured and 20 ruptured), as well as with Western blot (12 unruptured and 12 ruptured).
RESULTS:
Ruptured IA walls had more TUNEL-positive cells than unruptured walls (P < .001). Few cells positive for cleaved caspase-3 were detected. Cleaved caspase-9 (intrinsic activation of apoptosis) was significantly increased in ruptured IA walls, whereas cleaved caspase-8 (extrinsic activation of apoptosis) was not detected. Increased expression of hemeoxygenase-1, a marker for oxidative stress, was associated with IA wall degeneration and rupture.
CONCLUSION:
Our results show that programmed cell death is activated in the IA wall via the intrinsic pathway. High oxidative stress in the IA wall is probably a significant cause of the intrinsic activation of cell death.
Collapse
Affiliation(s)
| | | | - Arto Liiman
- Neurosurgery Research Group, Biomedicum Helsinki,
| | - Marc Baumann
- Protein Chemistry/Proteomics Laboratory, Institute of Biomedicine, University of Helsinki, Helsinki, Finland
| | - Robert M. Friedlander
- Department of Neurological Surgery, University of Pittsburgh, Pittsburgh, Pennsylvania
- Neuroapoptosis Laboratory, Harvard Medical School, Boston, Massachusetts
| | - Juha Hernesniemi
- Neurosurgery Research Group, Biomedicum Helsinki,
- Department of Neurosurgery, Helsinki University Central Hospital, Helsinki, Finland
| | - Marko Kangasniemi
- Neurosurgery Research Group, Biomedicum Helsinki,
- Department of Radiology, University of Helsinki and HUS Radiology (Medical Imaging Center), Helsinki, Finland
| | - Mika Niemelä
- Neurosurgery Research Group, Biomedicum Helsinki,
- Department of Neurosurgery, Helsinki University Central Hospital, Helsinki, Finland
| | - Aki Laakso
- Neurosurgery Research Group, Biomedicum Helsinki,
- Department of Neurosurgery, Helsinki University Central Hospital, Helsinki, Finland
| | - Juhana Frösen
- Neurosurgery Research Group, Biomedicum Helsinki,
- Department of Neurosurgery, Helsinki University Central Hospital, Helsinki, Finland
- Neuroapoptosis Laboratory, Harvard Medical School, Boston, Massachusetts
| |
Collapse
|
57
|
Michel JB, Delbosc S, Ho-Tin-Noé B, Leseche G, Nicoletti A, Meilhac O, Martin-Ventura JL. From intraplaque haemorrhages to plaque vulnerability. J Cardiovasc Med (Hagerstown) 2012; 13:628-34. [DOI: 10.2459/jcm.0b013e328357face] [Citation(s) in RCA: 35] [Impact Index Per Article: 2.9] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/11/2023]
|
58
|
Cell stress proteins in atherothrombosis. OXIDATIVE MEDICINE AND CELLULAR LONGEVITY 2012; 2012:232464. [PMID: 22792412 PMCID: PMC3389727 DOI: 10.1155/2012/232464] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 03/30/2012] [Accepted: 05/14/2012] [Indexed: 01/13/2023]
Abstract
Cell stress proteins (CSPs) are a large and heterogenous family of proteins, sharing two main characteristics: their levels and/or location are modified under stress and most of them can exert a chaperon function inside the cells. Nonetheless, they are also involved in the modulation of several mechanisms, both at the intracellular and the extracellular compartments. There are more than 100 proteins belonging to the CSPs family, among them the thioredoxin (TRX) system, which is the focus of the present paper. TRX system is composed of several proteins such as TRX and peroxiredoxin (PRDX), two thiol-containing enzymes that are key players in redox homeostasis due to their ability to scavenge potential harmful reactive oxygen species. In addition to their main role as antioxidants, recent data highlights their function in several processes such as cell signalling, immune inflammatory responses, or apoptosis, all of them key mechanisms involved in atherothrombosis. Moreover, since TRX and PRDX are present in the pathological vascular wall and can be secreted under prooxidative conditions to the circulation, several studies have addressed their role as diagnostic, prognostic, and therapeutic biomarkers of cardiovascular diseases (CVDs).
Collapse
|
59
|
Pincemail J, Defraigne JO, Cheramy-Bien JP, Dardenne N, Donneau AF, Albert A, Labropoulos N, Sakalihasan N. On the potential increase of the oxidative stress status in patients with abdominal aortic aneurysm. Redox Rep 2012; 17:139-44. [PMID: 22732574 DOI: 10.1179/1351000212y.0000000012] [Citation(s) in RCA: 28] [Impact Index Per Article: 2.3] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/16/2022] Open
Abstract
BACKGROUND Abdominal aortic aneurysm (AAA) is a major cause of preventable deaths in older patients. Oxidative stress has been suggested to play a key role in the pathogenesis of AAA. However, only few studies have been conducted to evaluate the blood oxidative stress status of AAA patients. METHODS AND RESULTS Twenty seven AAA patients (mean age of 70 years) divided into two groups according to AAA size (≤ 50 or > 50 mm) were compared with an age-matched group of 18 healthy subjects. Antioxidants (vitamins C and E, β-carotene, glutathione, thiols, and ubiquinone), trace elements (selenium, copper, zinc, and copper/zinc ratio) and markers of oxidative damage to lipids (lipid peroxides, antibodies against oxidized patients, and isoprostanes) were measured in each subject. The comparison of the three groups by ordinal logistic regression showed a significant decrease of the plasma levels of vitamin C (P = 0.011), α-tocopherol (P = 0.016) but not when corrected for cholesterol values, β-carotene (P = 0.0096), ubiquinone (P = 0.014), zinc (P = 0.0035), and of selenium (P = 0.0038), as AAA size increased. By contrast, specific markers of lipid peroxidation such as the Cu/Zn ratio (P = 0.046) and to a lesser extent isoprostanes (P = 0.052) increased. CONCLUSION The present study emphasizes the potential role of the oxidative stress in AAA disease and suggests that an antioxidant therapy could be of interest to delay AAA progression.
Collapse
Affiliation(s)
- J Pincemail
- Department of Cardiovascular Surgery, University of Liège, CHU Sart Tilman, Liège, Belgium.
| | | | | | | | | | | | | | | |
Collapse
|
60
|
Koole D, Hurks R, Schoneveld A, Vink A, Golledge J, Moran CS, de Kleijn DP, van Herwaarden JA, de Vries JP, Laman JD, Huizinga R, Pasterkamp G, Moll FL. Osteoprotegerin Is Associated With Aneurysm Diameter and Proteolysis in Abdominal Aortic Aneurysm Disease. Arterioscler Thromb Vasc Biol 2012; 32:1497-504. [DOI: 10.1161/atvbaha.111.243592] [Citation(s) in RCA: 44] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
Abstract
Objective—
Serum osteoprotegerin (OPG) concentrations have previously been associated with growth of abdominal aortic aneurysms (AAAs). In vitro experiments showed that OPG promotes matrix metalloprotease (MMP) release from monocytes and vascular smooth muscle cells. We hypothesized that OPG expression is increased in human AAAs and is associated with proteolysis.
Methods and Results—
AAA biopsies were collected from 329 patients. We assessed the concentrations of OPG, cathepsins A, B, and S as well as the activity of MMP-2 and MMP-9. The AAA wall infiltration by macrophages, lymphocytes, and plasma cells was estimated by immunohistochemistry. The concentration of OPG correlated positively with aortic diameter (<55 mm: 16.1 [5.8–28.7], 55–70 mm: 21.9 [10.2–36.0], >70 mm: 24.0 [13.5–52.9] ng OPG/mg total amount of protein,
P
=0.020), cathepsin A (
r
=0.221,
P
=0.005), B (
r
=0.384,
P
<0.001), and S (
r
=0.467, P<0.001), MMP-2 (
r
=0.180,
P
<0.001), MMP-9 (
r
=0.178, P<0.001), and the number of lymphocytes (
P
<0.001) and plasma cells (
P
=0.001). OPG immunostaining was predominantly demonstrated in plasma cells.
Conclusion—
The concentration of aortic wall OPG is positively associated with established markers of AAA severity and pathogenesis. OPG appeared to be associated with lymphocytes and plasma cells. These human data support previous experimental data suggesting a role for OPG in AAA pathogenesis.
Collapse
Affiliation(s)
- Dave Koole
- From the Department of Vascular Surgery (D.K., R.H., J.v.H., F.L.M.), Department of Experimental Cardiology (D.K., R.H., A.S., D.P.d.K., G.P.), and Department of Pathology (A.V.), University Medical Center Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, Harvard Medical School, Boston, MA (R.H.); Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands (A.S., D.P.d.K.); Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Australia
| | - Rob Hurks
- From the Department of Vascular Surgery (D.K., R.H., J.v.H., F.L.M.), Department of Experimental Cardiology (D.K., R.H., A.S., D.P.d.K., G.P.), and Department of Pathology (A.V.), University Medical Center Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, Harvard Medical School, Boston, MA (R.H.); Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands (A.S., D.P.d.K.); Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Australia
| | - Arjan Schoneveld
- From the Department of Vascular Surgery (D.K., R.H., J.v.H., F.L.M.), Department of Experimental Cardiology (D.K., R.H., A.S., D.P.d.K., G.P.), and Department of Pathology (A.V.), University Medical Center Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, Harvard Medical School, Boston, MA (R.H.); Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands (A.S., D.P.d.K.); Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Australia
| | - Aryan Vink
- From the Department of Vascular Surgery (D.K., R.H., J.v.H., F.L.M.), Department of Experimental Cardiology (D.K., R.H., A.S., D.P.d.K., G.P.), and Department of Pathology (A.V.), University Medical Center Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, Harvard Medical School, Boston, MA (R.H.); Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands (A.S., D.P.d.K.); Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Australia
| | - Jonathan Golledge
- From the Department of Vascular Surgery (D.K., R.H., J.v.H., F.L.M.), Department of Experimental Cardiology (D.K., R.H., A.S., D.P.d.K., G.P.), and Department of Pathology (A.V.), University Medical Center Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, Harvard Medical School, Boston, MA (R.H.); Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands (A.S., D.P.d.K.); Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Australia
| | - Corey S. Moran
- From the Department of Vascular Surgery (D.K., R.H., J.v.H., F.L.M.), Department of Experimental Cardiology (D.K., R.H., A.S., D.P.d.K., G.P.), and Department of Pathology (A.V.), University Medical Center Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, Harvard Medical School, Boston, MA (R.H.); Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands (A.S., D.P.d.K.); Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Australia
| | - Dominique P. de Kleijn
- From the Department of Vascular Surgery (D.K., R.H., J.v.H., F.L.M.), Department of Experimental Cardiology (D.K., R.H., A.S., D.P.d.K., G.P.), and Department of Pathology (A.V.), University Medical Center Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, Harvard Medical School, Boston, MA (R.H.); Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands (A.S., D.P.d.K.); Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Australia
| | - Joost A. van Herwaarden
- From the Department of Vascular Surgery (D.K., R.H., J.v.H., F.L.M.), Department of Experimental Cardiology (D.K., R.H., A.S., D.P.d.K., G.P.), and Department of Pathology (A.V.), University Medical Center Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, Harvard Medical School, Boston, MA (R.H.); Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands (A.S., D.P.d.K.); Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Australia
| | - Jean-Paul de Vries
- From the Department of Vascular Surgery (D.K., R.H., J.v.H., F.L.M.), Department of Experimental Cardiology (D.K., R.H., A.S., D.P.d.K., G.P.), and Department of Pathology (A.V.), University Medical Center Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, Harvard Medical School, Boston, MA (R.H.); Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands (A.S., D.P.d.K.); Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Australia
| | - Jon D. Laman
- From the Department of Vascular Surgery (D.K., R.H., J.v.H., F.L.M.), Department of Experimental Cardiology (D.K., R.H., A.S., D.P.d.K., G.P.), and Department of Pathology (A.V.), University Medical Center Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, Harvard Medical School, Boston, MA (R.H.); Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands (A.S., D.P.d.K.); Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Australia
| | - Ruth Huizinga
- From the Department of Vascular Surgery (D.K., R.H., J.v.H., F.L.M.), Department of Experimental Cardiology (D.K., R.H., A.S., D.P.d.K., G.P.), and Department of Pathology (A.V.), University Medical Center Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, Harvard Medical School, Boston, MA (R.H.); Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands (A.S., D.P.d.K.); Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Australia
| | - Gerard Pasterkamp
- From the Department of Vascular Surgery (D.K., R.H., J.v.H., F.L.M.), Department of Experimental Cardiology (D.K., R.H., A.S., D.P.d.K., G.P.), and Department of Pathology (A.V.), University Medical Center Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, Harvard Medical School, Boston, MA (R.H.); Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands (A.S., D.P.d.K.); Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Australia
| | - Frans L. Moll
- From the Department of Vascular Surgery (D.K., R.H., J.v.H., F.L.M.), Department of Experimental Cardiology (D.K., R.H., A.S., D.P.d.K., G.P.), and Department of Pathology (A.V.), University Medical Center Utrecht, Utrecht, The Netherlands; Department of Vascular Surgery, Harvard Medical School, Boston, MA (R.H.); Interuniversity Cardiology Institute of the Netherlands, Utrecht, The Netherlands (A.S., D.P.d.K.); Vascular Biology Unit, School of Medicine, James Cook University, Townsville, Australia
| |
Collapse
|
61
|
Martin-Ventura JL. Novel insights in oxidative stress on human atherothrombosis. Vascul Pharmacol 2012. [DOI: 10.1016/j.vph.2011.08.100] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022]
|
62
|
Metabolomic study of plasma of patients with abdominal aortic aneurysm. Anal Bioanal Chem 2012; 403:1651-60. [DOI: 10.1007/s00216-012-5982-y] [Citation(s) in RCA: 19] [Impact Index Per Article: 1.6] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/29/2011] [Revised: 03/25/2012] [Accepted: 03/26/2012] [Indexed: 10/28/2022]
|
63
|
Ciborowski M, Teul J, Martin-Ventura JL, Egido J, Barbas C. Metabolomics with LC-QTOF-MS permits the prediction of disease stage in aortic abdominal aneurysm based on plasma metabolic fingerprint. PLoS One 2012; 7:e31982. [PMID: 22384120 PMCID: PMC3286447 DOI: 10.1371/journal.pone.0031982] [Citation(s) in RCA: 53] [Impact Index Per Article: 4.4] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/15/2011] [Accepted: 01/16/2012] [Indexed: 11/23/2022] Open
Abstract
Abdominal aortic aneurysm (AAA) is a permanent and localized aortic dilation, defined as aortic diameter ≥3 cm. It is an asymptomatic but potentially fatal condition because progressive enlargement of the abdominal aorta is spontaneously evolving towards rupture. Biomarkers may help to explain pathological processes of AAA expansion, and allow us to find novel therapeutic strategies or to determine the efficiency of current therapies. Metabolomics seems to be a good approach to find biomarkers of AAA. In this study, plasma samples of patients with large AAA, small AAA, and controls were fingerprinted with LC-QTOF-MS. Statistical analysis was used to compare metabolic fingerprints and select metabolites that showed a significant change. Results presented here reveal that LC-QTOF-MS based fingerprinting of plasma from AAA patients is a very good technique to distinguish small AAA, large AAA, and controls. With the use of validated PLS-DA models it was possible to classify patients according to the disease stage and predict properly the stage of additional AAA patients. Identified metabolites indicate a role for sphingolipids, lysophospholipids, cholesterol metabolites, and acylcarnitines in the development and progression of AAA. Moreover, guanidinosuccinic acid, which mimics nitric oxide in terms of its vasodilatory action, was found as a strong marker of large AAA.
Collapse
Affiliation(s)
- Michal Ciborowski
- CEMBIO (Center for Metabolomics and Bioanalysis), Facultad de Farmacia, Universidad CEU San Pablo, Madrid, Spain
- Department of Physical Chemistry, Medical University of Bialystok, Bialystok, Poland
| | - Joanna Teul
- CEMBIO (Center for Metabolomics and Bioanalysis), Facultad de Farmacia, Universidad CEU San Pablo, Madrid, Spain
- Department of Pharmaceutical Analysis, Medical University of Bialystok, Bialystok, Poland
| | - Jose Luis Martin-Ventura
- Vascular Research Laboratory, IIS-Fundación Jiménez Díaz, Madrid, Spain
- Autónoma University, Madrid, Spain
| | - Jesús Egido
- Vascular Research Laboratory, IIS-Fundación Jiménez Díaz, Madrid, Spain
- Autónoma University, Madrid, Spain
| | - Coral Barbas
- CEMBIO (Center for Metabolomics and Bioanalysis), Facultad de Farmacia, Universidad CEU San Pablo, Madrid, Spain
- * E-mail:
| |
Collapse
|
64
|
Sun J, Sukhova GK, Zhang J, Chen H, Sjöberg S, Libby P, Xiang M, Wang J, Peters C, Reinheckel T, Shi GP. Cathepsin L activity is essential to elastase perfusion-induced abdominal aortic aneurysms in mice. Arterioscler Thromb Vasc Biol 2012; 31:2500-8. [PMID: 21868704 DOI: 10.1161/atvbaha.111.230201] [Citation(s) in RCA: 61] [Impact Index Per Article: 5.1] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/26/2023]
Abstract
OBJECTIVE The development of abdominal aortic aneurysms (AAA) requires extensive aortic wall matrix degradation. Human AAA lesions express high levels of cathepsin L (CatL), one of the most potent mammalian elastases. Whether this protease participates directly in AAA pathogenesis, however, is unknown. METHODS AND RESULTS We generated experimental AAA with aortic elastase perfusion in mice and established an essential role of CatL in AAA formation. After 14 days postperfusion, most wild-type (Ctsl(+/+)) mice developed AAA, but none of the CatL-deficient (Ctsl(-/-)) mice did. AAA lesion macrophage contents, CD4(+) T cell numbers, CD31(+) and laminin-5 angiogenic fragment γ2(+) microvessel numbers, and elastin fragmentation were all significantly lower in Ctsl(-/-) mice than in Ctsl(+/+) mice. While lesions from Ctsl(-/-) mice contained fewer Ki67(+) proliferating cells than did Ctsl(+/+) mice, the absence of CatL did not affect lesion apoptotic cell contents or medial smooth-muscle cell loss significantly. Mechanistic studies indicated that the absence of CatL reduced lesion chemokine monocyte chemotactic protein-1 content, macrophage and T-cell in vitro transmigration, and angiogenesis, and altered the expression and activities of matrix metalloproteinases and other cysteinyl cathepsins in inflammatory cells, vascular cells, and AAA lesions. CONCLUSION CatL contributes to AAA formation by promoting lesion inflammatory cell accumulation, angiogenesis, and protease expression.
Collapse
Affiliation(s)
- Jiusong Sun
- Department of Medicine, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA
| | | | | | | | | | | | | | | | | | | | | |
Collapse
|
65
|
Abstract
Reactive oxygen species (ROS), which include superoxide anions and peroxides, induce oxidative stress, contributing to the initiation and progression of cardiovascular diseases involving atherosclerosis. The endogenous and exogenous factors hypercholesterolemia, hyperglycemia, hypertension, and shear stress induce various enzyme systems such as nicotinamide adenine dinucleotide (phosphate) oxidase, xanthine oxidase, and lipoxygenase in vascular and immune cells, which generate ROS. Besides inducing oxidative stress, ROS mediate signaling pathways involved in monocyte adhesion and infiltration, platelet activation, and smooth muscle cell migration. A number of antioxidant enzymes (e.g., superoxide dismutases, catalase, glutathione peroxidases, and peroxiredoxins) regulate ROS in vascular and immune cells. Atherosclerosis results from a local imbalance between ROS production and these antioxidant enzymes. In this review, we will discuss 1) oxidative stress and atherosclerosis, 2) ROS-dependent atherogenic signaling in endothelial cells, macrophages, and vascular smooth muscle cells, 3) roles of peroxidases in atherosclerosis, and 4) antioxidant drugs and therapeutic perspectives.
Collapse
Affiliation(s)
- Jong-Gil Park
- Division of Life and Pharmaceutical Sciences, Ewha Womans University, Seoul, Korea
| | | |
Collapse
|
66
|
Quantitative mass spectrometry analysis using PAcIFIC for the identification of plasma diagnostic biomarkers for abdominal aortic aneurysm. PLoS One 2011; 6:e28698. [PMID: 22163325 PMCID: PMC3233585 DOI: 10.1371/journal.pone.0028698] [Citation(s) in RCA: 29] [Impact Index Per Article: 2.2] [Reference Citation Analysis] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/15/2011] [Accepted: 11/14/2011] [Indexed: 01/13/2023] Open
Abstract
BACKGROUND Abdominal aortic aneurysm (AAA) is characterized by increased aortic vessel wall diameter (>1.5 times normal) and loss of parallelism. This disease is responsible for 1-4% mortality occurring on rupture in males older than 65 years. Due to its asymptomatic nature, proteomic techniques were used to search for diagnostic biomarkers that might allow surgical intervention under nonlife threatening conditions. METHODOLOGY/PRINCIPAL FINDINGS Pooled human plasma samples of 17 AAA and 17 control patients were depleted of the most abundant proteins and compared using a data-independent shotgun proteomic strategy, Precursor Acquisition Independent From Ion Count (PAcIFIC), combined with spectral counting and isobaric tandem mass tags. Both quantitative methods collectively identified 80 proteins as statistically differentially abundant between AAA and control patients. Among differentially abundant proteins, a subgroup of 19 was selected according to Gene Ontology classification and implication in AAA for verification by Western blot (WB) in the same 34 individual plasma samples that comprised the pools. From the 19 proteins, 12 were detected by WB. Five of them were verified to be differentially up-regulated in individual plasma of AAA patients: adiponectin, extracellular superoxide dismutase, protein AMBP, kallistatin and carboxypeptidase B2. CONCLUSIONS/SIGNIFICANCE Plasma depletion of high abundance proteins combined with quantitative PAcIFIC analysis offered an efficient and sensitive tool for the screening of new potential biomarkers of AAA. However, WB analysis to verify the 19 PAcIFIC identified proteins of interest proved inconclusive save for five proteins. We discuss these five in terms of their potential relevance as biological markers for use in AAA screening of population at risk.
Collapse
|
67
|
Proteomic analysis of intra-arterial thrombus secretions reveals a negative association of clusterin and thrombospondin-1 with abdominal aortic aneurysm. Atherosclerosis 2011; 219:432-9. [DOI: 10.1016/j.atherosclerosis.2011.08.013] [Citation(s) in RCA: 36] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 03/15/2011] [Revised: 07/01/2011] [Accepted: 08/07/2011] [Indexed: 11/18/2022]
|
68
|
Pulinx B, Hellenthal FAMVI, Hamulyák K, van Dieijen-Visser MP, Schurink GWH, Wodzig WKWH. Differential protein expression in serum of abdominal aortic aneurysm patients - a proteomic approach. Eur J Vasc Endovasc Surg 2011; 42:563-70. [PMID: 21843957 DOI: 10.1016/j.ejvs.2011.07.019] [Citation(s) in RCA: 8] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 04/21/2011] [Accepted: 07/16/2011] [Indexed: 11/19/2022]
Abstract
OBJECTIVE The aim of the study is to investigate the differential expression of proteins in serum of abdominal aortic aneurysm (AAA) patients in relation to aneurysm size (D(max)) and progression. METHODS Two-dimensional differential in-gel electrophoresis (2D-DIGE) together with tandem mass spectrometry (MS/MS) was used to analyse the serum proteome from patients with small (D(max) 30-54 mm) AAA, either stable (increase D(max) <5 mm year⁻¹; n = 8) or progressive (increase D(max) ≥5 mm year⁻¹; n = 8), and large (D(max) ≥ 55 mm; n = 8) AAA. The identified proteins were quantitatively validated in a larger population (n = 80). RESULTS Several proteins were differentially expressed in serum of small stable, small progressive and large AAA. Three validated proteins (immunoglobulin G (IgG), α1-antitrypsin (α1-AT) and Factor XII activity) showed strong correlation with D(max). Size combined with either Factor XII activity or α1-antitrypsin had minimal effect on the prognostic value in predicting aneurysm progression compared with size alone (area under the curve (AUC), 0.85; 95% confidence interval (CI), 0.73-0.97; p < 0.001 and AUC, 0.85; 95% CI, 0.72-0.98; p < 0.001 vs. AUC, 0.83; 95% CI, 0.71-0.96; p < 0.001, respectively). CONCLUSION The present study indicates that both Factor XII and α1-antitrypsin are found in increased amounts in the serum of patients with expanding AAA. However, combination of either Factor XII or α1-antitrypsin with aneurysm diameter had little effect on prediction of aneurysm progression versus diameter alone.
Collapse
Affiliation(s)
- B Pulinx
- Department of Clinical Chemistry, Maastricht University Medical Centre, Maastricht, The Netherlands
| | | | | | | | | | | |
Collapse
|